Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | 3M Innovative Properties Co | 68 |
| 2 | Haptogen Ltd | 18 |
| 3 | Grünenthal GmbH | 13 |
| 4 | The University of Texas System | 10 |
| 5 | Columbia University | 9 |
| 6 | Astellas Pharma Inc | 8 |
| 7 | Council of Scientific and Industrial Research | 7 |
| 8 | Henkel AG and Co KGaA | 7 |
| 9 | Solventum Intellectual Properties Co | 7 |
| 10 | University of California, San Diego | 7 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 276 |
| 2 | A61P | Therapeutic activity (drug indications) | 236 |
| 3 | C12N | Microorganisms, enzymes | 162 |
| 4 | Y02A | Climate change adaptation | 130 |
| 5 | C07K | Peptides | 111 |
| 6 | G01N | Investigating / analysing materials | 108 |
| 7 | A01N | Preservation of bodies; biocides; pest repellents | 102 |
| 8 | C12Q | Measuring/testing involving enzymes | 73 |
| 9 | C12R | 56 | |
| 10 | C07D | Heterocyclic compounds | 53 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Proteins specific for pyoverdine and pyochelin | 2018 | Pieris Pharmaceuticals GmbH | 1 |
| A novel protein specific for pyoverdine and pyokerin | 2021 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 0 |
| Fusion molecules with binding specificity for pyoverdin type I, II and III and pyoquelin | 2018 | SANOFI | 0 |
| Novel proteins specific for pyoverdine and pyochelin | 2017 | Pieris Pharmaceuticals GmbH | 0 |
| Specific proteins for pyoverdin and pyoquelin | 2017 | SANOFI | 0 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Bacterial Genetics and Biotechnology | 2 |
| 2 | Microbial Fuel Cells and Bioremediation | 2 |
| 3 | Photosynthetic Processes and Mechanisms | 2 |
| 4 | Plant-Microbe Interactions and Immunity | 2 |
| 5 | Porphyrin Metabolism and Disorders | 2 |
| 6 | Antibiotic Resistance in Bacteria | 1 |
| 7 | Cassava research and cyanide | 1 |
| 8 | Legume Nitrogen Fixing Symbiosis | 1 |
| 9 | Nosocomial Infections in ICU | 1 |
| 10 | Plant Pathogenic Bacteria Studies | 1 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | H. Budzikiewicz | University of Cologne | 37 |
| 2 | Isabelle J. Schalk | Centre National de la Recherche Scientifique | 31 |
| 3 | Jean‐Marie Meyer | Centre National de la Recherche Scientifique | 31 |
| 4 | Iain L. Lamont | University of Otago | 24 |
| 5 | Pierre Cornélis | Vrije Universiteit Brussel | 22 |
| 6 | Christine Baysse | Vrije Universiteit Brussel | 12 |
| 7 | F. Pattus | Centre National de la Recherche Scientifique | 11 |
| 8 | Ashleigh S. Griffin | University of Oxford | 9 |
| 9 | K. Taraz | University of Cologne | 9 |
| 10 | Paolo Visca | Roma Tre University | 9 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Iron and <i>Pseudomonas aeruginosa</i> biofilm formation | 2005 | 794 | Bacterial Genetics and Biotechnology |
| Siderophore-mediated signaling regulates virulence factor production in <i>Pseudomonas</i> <i>aeruginosa</i> | 2002 | 579 | Bacterial Genetics and Biotechnology |
| Pyoverdin is essential for virulence of Pseudomonas aeruginosa | 1996 | 525 | Bacterial Genetics and Biotechnology |
| Pyoverdines: pigments, siderophores and potential taxonomic markers of fluorescent Pseudomonas species | 2000 | 441 | Bacterial Genetics and Biotechnology |
| Dispersed cells represent a distinct stage in the transition from bacterial biofilm to planktonic lifestyles | 2014 | 417 | Bacterial Genetics and Biotechnology |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Pyoverdin?
What are the leading patent assignees in the Pyoverdin field?
Who are the most prolific researchers publishing on Pyoverdin?
What are the main patent classification areas for Pyoverdin-related inventions?
What are the most-cited papers on Pyoverdin and its biological role?